Evidence map›Paper›PMID 39340057›Full record

ArticleVaccines2024

How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study.

Olga Tsyruk, Gilaad G Kaplan, Paul R Fortin, Carol A Hitchon, Vinod Chandran, Maggie J Larché, Antonio Avina-Zubieta, Gilles Boire, Ines Colmegna, Diane Lacaille and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Olga TsyrukDepartment of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.
Gilaad G KaplanDivision of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB T2N 4Z6, Canada.ORCID 0000-0003-2719-0556
Paul R FortinCentre de Recherche ARThrite-UL, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec City, QC G1V 4G2, Canada.
Carol A HitchonDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada.
Vinod ChandranSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada.
Maggie J LarchéDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Antonio Avina-ZubietaArthritis Research Canada and Division of Rheumatology, University of British Columbia, Vancouver, BC V5Y 3P2, Canada.
Gilles BoireDivision of Rheumatology, Department of Medicine, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0003-2481-5821
Ines ColmegnaDepartment of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.
Diane LacailleArthritis Research Canada and Division of Rheumatology, University of British Columbia, Vancouver, BC V5Y 3P2, Canada.
Nadine LalondeCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.
Laurie ProulxCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.
Dawn P RichardsCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.
Natalie BoivinCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.
Christopher DeBowCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.
Lucy Kovalova-WoodCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.
Deborah PalecznyCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.
Linda WilhelmCanadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada.ORCID 0009-0009-9719-318X
Luck LukusaThe Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.
Daniel PereiraSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada.
Jennifer Lf LeeThe Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.ORCID 0000-0002-5501-0017
Sasha BernatskyDepartment of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.ORCID 0000-0002-9515-2802
On Behalf Of The Succeed Investigative Team

Funding

Public Health Agency of Canada 2122-HQ-000070
6 · The paper itself

Abstract

We were tasked by Canada's COVID-19 Immunity Task Force to describe severe adverse events (SAEs) associated with emergency department (ED) visits and/or hospitalizations in individuals with immune-mediated inflammatory diseases (IMIDs). At eight Canadian centres, data were collected from adults with rheumatoid arthritis (RA), axial spondyloarthritis (AxS), systemic lupus (SLE), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD). We administered questionnaires, analyzing SAEs experienced within 31 days following SARS-CoV-2 vaccination. About two-thirds (63%) of 1556 participants were female; the mean age was 52.5 years. The BNT162b2 (Pfizer) vaccine was the most common, with mRNA-1273 (Moderna) being second. A total of 49% of participants had IBD, 27.4% had RA, 14.3% had PsA, 5.3% had SpA, and 4% had SLE. Twelve (0.77% of 1556 participants) SAEs leading to an ED visit or hospitalization were self-reported, occurring in 11 participants. SAEs included six (0.39% of 1556 participants) ED visits (including one due to Bell's Palsy 31 days after first vaccination) and six (0.39% of 1556 participants) hospitalizations (including one due to Guillain-Barré syndrome 15 days after the first vaccination). Two SAEs included pericarditis, one involved SLE (considered a serious disease flare), and one involved RA. Thus, in the 31 days after SARS-CoV-2 vaccination in our IMID sample, very few serious adverse events occurred. As SARS-CoV2 continues to be a common cause of death, our findings may help optimize vaccination acceptance.

Indexed as

COVID-19 vaccine safetyimmune-mediated inflammatory diseasesserious adverse events

Identifiers

PMID39340057
PMCPMC11436126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.